Senaste besöket: Aktuellt datum och tid: lör 26 maj 2018, 07:56


Alla tidsangivelser är UTC + 1 timme [ Sommartid ]




Ny tråd Svara på tråd  [ 1 inlägg ] 
Författare Meddelande
 Inläggsrubrik: Application of Nanotrap technology for high sensitivity meas
InläggPostat: mån 21 aug 2017, 23:03 
Föreningsmedlem

Blev medlem: tor 18 jun 2009, 00:19
Inlägg: 1522
Application of Nanotrap technology
for high sensitivity measurement of urinary
outer surface protein A carboxyl-terminus
domain in early stage Lyme borreliosis

Abstract
Objectives: Prompt antibiotic treatment of early stage Lyme borreliosis (LB) prevents progression to severe multisystem
disease. There is a clinical need to improve the diagnostic specificity of early stage Lyme assays in the period prior
to the mounting of a robust serology response. Using a novel analyte harvesting nanotechnology, Nanotrap particles,
we evaluated urinary Borrelia Outer surface protein A (OspA) C-terminus peptide in early stage LB before and after
treatment, and in patients suspected of late stage disseminated LB.
Method: We employed Nanotrap particles to concentrate urinary OspA and used a highly specific anti-OspA monoclonal
antibody (mAb) as a detector of the C-terminus peptides. We mapped the mAb epitope to a narrow specific
OspA C-terminal domain OspA236-239 conserved across infectious Borrelia species but with no homology to human
proteins and no cross-reactivity with relevant viral and non-Borrelia bacterial proteins. 268 urine samples from patients
being evaluated for all categories of LB were collected in a LB endemic area. The urinary OspA assay, blinded to
outcome, utilized Nanotrap particle pre-processing, western blotting to evaluate the OspA molecular size, and OspA
peptide competition for confirmation.
Results: OspA test characteristics: sensitivity 1.7 pg/mL (lowest limit of detection), % coefficient of variation
(CV) = 8 %, dynamic range 1.7–30 pg/mL. Pre-treatment, 24/24 newly diagnosed patients with an erythema migrans
(EM) rash were positive for urinary OspA while false positives for asymptomatic patients were 0/117 (Chi squared
p < 10−6
). For 10 patients who exhibited persistence of the EM rash during the course of antibiotic therapy, 10/10
were positive for urinary OspA. Urinary OspA of 8/8 patients switched from detectable to undetectable following
symptom resolution post-treatment. Specificity of the urinary OspA test for the clinical symptoms was 40/40. Specificity
of the urinary OspA antigen test for later serology outcome was 87.5 % (21 urinary OspA positive/24 serology
positive, Chi squared p = 4.072e−15). 41 of 100 patients under surveillance for persistent LB in an endemic area were
positive for urinary OspA protein.
Conclusions: OspA urinary shedding was strongly linked to concurrent active symptoms (e.g. EM rash and arthritis),
while resolution of these symptoms after therapy correlated with urinary conversion to OspA negative.

https://caudwelllymedotnet.files.wordpr ... nology.pdf


Upp
Offline Profil  
 
Visa inlägg nyare än:  Sortera efter  
Ny tråd Svara på tråd  [ 1 inlägg ] 

Alla tidsangivelser är UTC + 1 timme [ Sommartid ]


Vilka är online

Användare som besöker denna kategori: Inga registrerade användare och 0 gäster


Du kan inte skapa nya trådar i denna kategori
Du kan inte svara på trådar i denna kategori
Du kan inte redigera dina inlägg i denna kategori
Du kan inte ta bort dina inlägg i denna kategori
Du kan inte bifoga filer i denna kategori

Hoppa till:  
cron
Powered by phpBB © 2000, 2002, 2005, 2007 phpBB Group
Theme created StylerBB.net & kodeki
Swedish translation by Peetra & phpBB Sweden © 2006-2008